Uncovering Mechanism and Efficacy of Salvia Miltiorrhiza-Safflower in Cerebral Ischemia-Reperfusion Injury.

TNF-ɑ/JNK signaling pathway cerebral ischemia herb-pair multiple targets

Journal

Neuroscience
ISSN: 1873-7544
Titre abrégé: Neuroscience
Pays: United States
ID NLM: 7605074

Informations de publication

Date de publication:
28 Nov 2023
Historique:
received: 17 09 2023
revised: 15 11 2023
accepted: 17 11 2023
pubmed: 1 12 2023
medline: 1 12 2023
entrez: 30 11 2023
Statut: aheadofprint

Résumé

Cerebral ischemia (CI) is the main cause of stroke morbidity and disability. This study aims to identify the early molecular regulation responsible for the therapeutic effectiveness of the Herb pair Danshen-Honghua (DH) for CI. The major targets of DH were identified by searching the public database of traditional Chinese medicine (TCM). In addition, GeneCards, Disgenet, and GeneMap databases in OMIM were used to determine the disease targets of CI. A total of 88 common targets of DH and CI were selected, a protein-protein interaction (PPI) network was established by Cytoscape, and 19 core targets were screened. These genes were primarily enriched in biological processes including wound healing, reaction to oxidative stress, and response to peptides, lipid and atherosclerosis, Age-rage signaling pathway, and TNF signaling pathway by KEGG and GO enrichments. The effective components of DH had stable binding to these key targets by molecular docking. Finally, it was verified that the mechanism of DH on CI treatment may be related to the activation of the TNF-α/JNK signaling pathway by establishing the middle cerebral artery occlusion (MCAO) rat model.

Identifiants

DOI: 10.1016/j.neuroscience.2023.11.021 PMID: 38036060
pubmed: 38036060
pii: S0306-4522(23)00517-1
doi: 10.1016/j.neuroscience.2023.11.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-11

Informations de copyright

Copyright © 2023 IBRO. Published by Elsevier Ltd. All rights reserved.

Auteurs

Yangyang Zhang (Y)

School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; Key Laboratory of TCM Encephalopathy of Zhejiang Province, Hangzhou, Zhejiang, China. Electronic address: zyy950909@126.com.

Jiayin Du (J)

The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Electronic address: 17857315343@163.com.

Weifeng Jin (W)

Key Laboratory of TCM Encephalopathy of Zhejiang Province, Hangzhou, Zhejiang, China; School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Electronic address: jin_weifeng@126.com.

Jiehong Yang (J)

School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; Key Laboratory of TCM Encephalopathy of Zhejiang Province, Hangzhou, Zhejiang, China. Electronic address: yjhong@zcmu.edu.cn.

Zhishan Ding (Z)

School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Electronic address: zjtcmdzs@163.com.

Yu He (Y)

Key Laboratory of TCM Encephalopathy of Zhejiang Province, Hangzhou, Zhejiang, China; School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Electronic address: heyu0923@sina.com.

Haitong Wan (H)

School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; Key Laboratory of TCM Encephalopathy of Zhejiang Province, Hangzhou, Zhejiang, China. Electronic address: whtong@126.com.

Li Yu (L)

School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, Zhejiang, China; Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang, China. Electronic address: yuli9119@126.com.

Classifications MeSH